Rebecca Bascom, MD
Pulmonary Disease · Hershey, PANPI 1548214083
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,915 of the $2,845 with a category attached, or 67.3%. United Therapeutics Corporation accounts for 84.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,409 and has fallen 94.3% since, to $138 in 2025.
Across 27 payments — averaging $105.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Boehringer Ingelheim$179
- GSK$104
- Bristol Myers Squibb$47
- AstraZeneca$35
- Genentech, Inc.$32
- plus $40 from 3 others
Across 184 payments — averaging $3056.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$331K
- Boehringer Ingelheim$119K
- E.r. Squibb & Sons, L.L.C.$60K
- Astrazeneca UK Limited$34K
- Roche Products Limited$14K
- Boehringer Ingelheim International GmbH$2K
- plus $3K from 3 others
What the payments were for
- Travel & lodging$1,91567%
- Food & beverage$85530%
- Education$753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 15 | $2,409 |
| Boehringer Ingelheim | 2 | $179 |
| GSK | 1 | $104 |
| Bristol Myers Squibb | 2 | $47 |
| AstraZeneca | 3 | $35 |
| Genentech, Inc. | 1 | $32 |
| Insmed, Inc. | 1 | $16 |
| Merck | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$138
- TRELEGY ELLIPTA$104
How this compares
$2,845 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $210,156 |
| XolairOmalizumab | 12 | $29,573 |
| Pirfenidone | 21 | $28,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,943 |
| Ventolin HfaAlbuterol Sulfate | 13 | $1,229 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $903 |
| Famotidine | 49 | $794 |
| Azithromycin | 24 | $778 |
| Montelukast Sodium | 21 | $556 |
| Pantoprazole Sodium | 28 | $466 |
| Fluticasone Propionate | 11 | $123 |
| Topiramate | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $179 | $210,15616 claims |
| Genentech, Inc.Xolair | $32 | $29,57312 claims |
| GSKTrelegy Ellipta | $104 | $20,94328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Hershey
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.